Literature DB >> 12520701

Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint.

Robin T Vollmer1, Peter A Humphrey.   

Abstract

Many have observed poor correlations between serum prostate-specific antigen (PSA) and tumor volume, and this noise undoubtedly reduces the diagnostic specificity of PSA. To explore this phenomenon, we addressed the problem from a theoretical viewpoint. Specifically, we used a compartmental model and first-order kinetics to develop the mathematics necessary to relate serum PSA to tumor volume. We found that the resulting model fit well the observed kinetic data of PSA measured after biopsy or prostatectomy. The model also predicted a linear relationship between PSA and the sum of volumes of benign and malignant tissues, but the coefficients for this linear equation are more complex than previously thought. They reflect not only how much PSA may be present in each tissue but also 3 rate parameters and the volume of serum. Much of the noise in the linkage between PSA and tumor volume is due to individual patient differences in the 3 rate parameters and in serum volume. Our model predicts that without ways to directly measure the several involved rate parameters, we will not be able to accurately predict tumor volume from PSA. Nevertheless, surrogates for the missing parameters may exist and could lead to statistical models that could improve the prediction of tumor volume.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12520701     DOI: 10.1309/UNAQ-JTFP-B1RQ-BQD4

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome.

Authors:  Guillermo Lorenzo; Víctor M Pérez-García; Alfonso Mariño; Luis A Pérez-Romasanta; Alessandro Reali; Hector Gomez
Journal:  J R Soc Interface       Date:  2019-08-14       Impact factor: 4.118

2.  Has blood volume an impact on serum PSA levels?

Authors:  Anton Ponholzer; Christian Temml; Stephan Madersbacher
Journal:  World J Urol       Date:  2009-08-27       Impact factor: 4.226

3.  The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach.

Authors:  David Basanta; Douglas W Strand; Ralf B Lukner; Omar E Franco; David E Cliffel; Gustavo E Ayala; Simon W Hayward; Alexander R A Anderson
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

4.  Tissue-scale, personalized modeling and simulation of prostate cancer growth.

Authors:  Guillermo Lorenzo; Michael A Scott; Kevin Tew; Thomas J R Hughes; Yongjie Jessica Zhang; Lei Liu; Guillermo Vilanova; Hector Gomez
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-16       Impact factor: 11.205

5.  PSA mass as a marker of prostate cancer progression after radical prostatectomy.

Authors:  Piotr Bryniarski; Andrzej Paradysz; Mieczyslaw Fryczkowski
Journal:  Med Sci Monit       Date:  2011-02

6.  Serum CA125 concentration has inverse correlation with metabolic syndrome.

Authors:  Nam-Seok Joo; Kyu-Nam Kim; Kyung Soo Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

7.  Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia.

Authors:  Jong Min Kim; Phil Hyun Song; Hyun Tae Kim; Ki Hak Moon
Journal:  Korean J Urol       Date:  2011-06-17

8.  Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine.

Authors:  Dominique Barbolosi; Ilyssa Summer; Christophe Meille; Raphaël Serre; Antony Kelly; Slimane Zerdoud; Claire Bournaud; Claire Schvartz; Michel Toubeau; Marie-Elisabeth Toubert; Isabelle Keller; David Taïeb
Journal:  Oncotarget       Date:  2017-06-13

9.  Association between carcinoembryonic antigen, carbohydrate antigen 19-9 and body mass index in colorectal cancer patients.

Authors:  Wei Chen; Qin Liu; Shu-Yun Tan; Yan-Hui Jiang
Journal:  Mol Clin Oncol       Date:  2013-07-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.